Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company leveraging artificial intelligence, has scheduled a webcast to discuss its second-quarter 2026 financial and operating results. The event, set for Aug. 14, 2026, at 9 a.m. ET, will be led by President and CEO Panna Sharma and members of the management team. The webcast will cover results for the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments related to the company's RADR® and Open-Medicine AI platforms. A replay will be available on the company's investor relations website after the event.
This announcement is significant because it comes at a pivotal time for Lantern Pharma. The company is not only advancing its clinical pipeline but also commercializing its AI capabilities. Notably, withZeta.ai, Lantern's multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for the company, which could be a key focus during the upcoming call. The integration of AI into drug discovery and development is a growing trend, and Lantern is positioning itself at the forefront by offering its proprietary technology to external researchers.
Lantern's clinical pipeline includes LP-184, an acylfulvene derivative being developed for various solid tumors, and LP-284, a TC-NER targeting compound for hematologic and solid tumors. Additionally, LP-300, a cisplatin analog, is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. These programs highlight the company's commitment to addressing significant unmet medical needs in oncology.
The company has also expanded its global footprint with an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. This international presence may enhance its ability to collaborate with researchers worldwide, further supporting the adoption of its AI platforms. The upcoming webcast will likely provide more details on how these initiatives are progressing and what they mean for the company's future growth.
Investors and stakeholders will be keen to hear about the financial performance of the quarter and any updates on the clinical trials, especially given the potential of LP-300 in the HARMONIC trial. The management team's commentary on upcoming milestones will be crucial in assessing the company's near-term prospects. The webcast also offers an opportunity for analysts and investors to gauge the progress of the RADR® platform and the commercial traction of withZeta.ai.
Lantern Pharma's dual focus on clinical development and AI platform commercialization could provide a diversified growth story. As the company continues to leverage artificial intelligence and machine learning to transform cancer therapy development, its ability to generate revenue from its AI tools may become an increasingly important part of its valuation. The Q2 results webcast will be a key event to monitor for insights into this evolving strategy.
For more details, the full press release is available at https://ibn.fm/l80kv. Additional information about Lantern Pharma can be found in its newsroom at https://ibn.fm/LTRN.
